Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
179
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 44 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 2 days agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 13, 2010 | Pazopanib | Health Canada CA | cancer not stated in this record | Marketed in Canada as VOTRIENT (DIN 02352303) under ATC L01EX03 PAZOPANIB. Indications are not published in the Drug Product Database — see… | DIN02352303 | approvedsource: Marketed | health-canada-dpd |
| Aug 5, 2010 | Trabectedin | Health Canada CA | cancer not stated in this record | Marketed in Canada as YONDELIS (DIN 02351528) under ATC L01CX01 TRABECTEDIN. Indications are not published in the Drug Product Database —… | DIN02351528 | approvedsource: Marketed | health-canada-dpd |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 5, 2010 | Interferon Beta-1b | Health Canada CA | cancer not stated in this record | Marketed in Canada as EXTAVIA (DIN 02337819) under ATC L03AB08 INTERFERON BETA-1B. Indications are not published in the Drug Product… | DIN02337819 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 28, 2010 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as LETROZOLE (DIN 02348969) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database —… | DIN02348969 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 25, 2010 | Hydroxyurea | Health Canada CA | cancer not stated in this record | Marketed in Canada as HYDROXYUREA (DIN 02343096) under ATC L01XX05 HYDROXYCARBAMIDE. Indications are not published in the Drug Product… | DIN02343096 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 4, 2010 | Azacitidine | Health Canada CA | cancer not stated in this record | Marketed in Canada as VIDAZA (DIN 02336707) under ATC L01BC07 AZACITIDINE. Indications are not published in the Drug Product Database — see… | DIN02336707 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 10, 2009 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEMODAL (DIN 02321262) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database —… | DIN02321262 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 24, 2009 | Degarelix | Health Canada CA | cancer not stated in this record | Marketed in Canada as FIRMAGON (DIN 02337037) under ATC L02BX02 DEGARELIX. Indications are not published in the Drug Product Database — see… | DIN02337037 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 2, 2009 | Topotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as TOPOTECAN FOR INJECTION (DIN 02333880) under ATC L01CE01 TOPOTECAN. Indications are not published in the Drug Product… | DIN02333880 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 29, 2009 | Sodium Iodide 131 I | Health Canada CA | cancer not stated in this record | Marketed in Canada as HICON (DIN 02482339) under ATC V10XA01 SODIUM IODIDE 131 I. Indications are not published in the Drug Product… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 16, 2009 | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE FOR INJECTION (DIN 02324210) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug… | DIN02324210 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 30, 2009 | Sodium Iodide 131 I | Health Canada CA | cancer not stated in this record | Marketed in Canada as DRAXIMAGE SODIUM IODIDE I131 SOLUTION, USP THERAPEUTIC (DIN 02329778) under ATC V10XA01 SODIUM IODIDE 131 I.… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 14, 2009 | Interferon Beta-1a | Health Canada CA | cancer not stated in this record | Marketed in Canada as REBIF (DIN 02318261) under ATC L03AB07 INTERFERON BETA-1A. Indications are not published in the Drug Product Database… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 31, 2009 | Vinorelbine | Health Canada CA | cancer not stated in this record | Marketed in Canada as VINORELBINE INJECTION (DIN 02265990) under ATC L01CA04 VINORELBINE. Indications are not published in the Drug Product… | DIN02265990 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 21, 2009 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEMODAL (DIN 02312816) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database —… | DIN02312816 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 26, 2009 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METOJECT (DIN 02320053) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database —… | DIN02320053 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 28, 2008 | Epirubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as EPIRUBICIN HYDROCHLORIDE INJECTION (DIN 02303892) under ATC L01DB03 EPIRUBICIN. Indications are not published in the… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 31, 2008 | Irinotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as IRINOTECAN FOR INJECTION (DIN 02312409) under ATC L01CE02 IRINOTECAN. Indications are not published in the Drug… | DIN02312409 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 30, 2008 | Nilotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TASIGNA (DIN 02315874) under ATC L01EA03 NILOTINIB. Indications are not published in the Drug Product Database — see… | DIN02315874 |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| withdrawnsource: Cancelled Post Marketsince Mar 8, 2022 |
| health-canada-dpd |
| May 5, 2010 | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACH-BICALUTAMIDE (DIN 02325985) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02325985 | approvedsource: Marketed | health-canada-dpd |
| May 3, 2010 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACH-LETROZOLE (DIN 02338459) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database… | DIN02338459 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jun 18, 2018 |
| health-canada-dpd |
| Apr 28, 2010 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as LETROZOLE (DIN 02347997) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database —… | DIN02347997 | withdrawnsource: Cancelled Post Marketsince Dec 10, 2013 | health-canada-dpd |
| Apr 28, 2010 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as MED-LETROZOLE (DIN 02322315) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database… | DIN02322315 | withdrawnsource: Dormantsince May 25, 2018 | health-canada-dpd |
| Apr 28, 2010 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-LETROZOLE (DIN 02309114) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database… | DIN02309114 | approvedsource: Marketed | health-canada-dpd |
| Apr 27, 2010 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as SANDOZ LETROZOLE (DIN 02344815) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product… | DIN02344815 | approvedsource: Marketed | health-canada-dpd |
| Apr 13, 2010 | Idarubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as IDARUBICIN HYDROCHLORIDE INJECTION (DIN 02337584) under ATC L01DB06 IDARUBICIN. Indications are not published in the… | DIN02337584 | withdrawnsource: Cancelled Post Marketsince Oct 7, 2021 | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jul 31, 2017 |
| health-canada-dpd |
| Feb 10, 2010 | Clofarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CLOLAR (DIN 02330407) under ATC L01BB06 CLOFARABINE. Indications are not published in the Drug Product Database — see… | DIN02330407 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Feb 1, 2016 |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Nov 24, 2009 | Degarelix | Health Canada CA | cancer not stated in this record | Marketed in Canada as FIRMAGON (DIN 02337029) under ATC L02BX02 DEGARELIX. Indications are not published in the Drug Product Database — see… | DIN02337029 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Aug 1, 2019 |
| health-canada-dpd |
| Oct 1, 2009 | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE FOR INJECTION, USP (DIN 02318741) under ATC L01BC05 GEMCITABINE. Indications are not published in the… | DIN02318741 | withdrawnsource: Cancelled Post Marketsince Aug 1, 2018 | health-canada-dpd |
| withdrawnsource: Dormantsince Jul 19, 2019 |
| health-canada-dpd |
| Sep 29, 2009 | Sodium Iodide 131 I | Health Canada CA | cancer not stated in this record | Marketed in Canada as HICON (DIN 02482320) under ATC V10XA01 SODIUM IODIDE 131 I. Indications are not published in the Drug Product… | DIN02482320 | withdrawnsource: Dormantsince Jul 19, 2019 | health-canada-dpd |
| Sep 29, 2009 | Sodium Iodide 131 I | Health Canada CA | cancer not stated in this record | Marketed in Canada as HICON (DIN 02327864) under ATC V10XA01 SODIUM IODIDE 131 I. Indications are not published in the Drug Product… | DIN02327864 | withdrawnsource: Dormantsince Jul 19, 2019 | health-canada-dpd |
| Sep 14, 2009 | Epirubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as EPIRUBICIN HYDROCHLORIDE INJECTION (DIN 02324091) under ATC L01DB03 EPIRUBICIN. Indications are not published in the… | DIN02324091 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Oct 28, 2025 |
| health-canada-dpd |
| Jul 1, 2009 | Asparaginase | Health Canada CA | cancer not stated in this record | Marketed in Canada as ERWINASE (DIN 02237815) under ATC L01XX02 ASPARAGINASE. Indications are not published in the Drug Product Database —… | DIN02237815 | withdrawnsource: Cancelled Post Marketsince Apr 9, 2021 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jun 30, 2009 | Sodium Iodide 131 I | Health Canada CA | cancer not stated in this record | Marketed in Canada as DRAXIMAGE SODIUM IODIDE I131 CAPSULES, USP THERAPEUTIC (DIN 02329743) under ATC V10XA01 SODIUM IODIDE 131 I.… | DIN02329743 | approvedsource: Marketed | health-canada-dpd |
| Jun 30, 2009 | Cladribine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CLADRIBINE INJECTION (DIN 02319918) under ATC L01BB04 CLADRIBINE. Indications are not published in the Drug Product… | DIN02319918 | approvedsource: Marketed | health-canada-dpd |
| Jun 29, 2009 | Vorinostat | Health Canada CA | cancer not stated in this record | Marketed in Canada as ZOLINZA (DIN 02327619) under ATC L01XH01 VORINOSTAT. Indications are not published in the Drug Product Database — see… | DIN02327619 | approvedsource: Marketed | health-canada-dpd |
| Jun 22, 2009 | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as BICALUTAMIDE (DIN 02325233) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02325233 | withdrawnsource: Cancelled Post Marketsince Jun 20, 2014 | health-canada-dpd |
| Jun 16, 2009 | Methyl Aminolevulinate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METVIX (DIN 02323273) under ATC L01XD03 METHYL AMINOLEVULINATE. Indications are not published in the Drug Product… | DIN02323273 | approvedsource: Marketed | health-canada-dpd |
| Jun 5, 2009 | Lapatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TYKERB (DIN 02326442) under ATC L01EH01 LAPATINIB. Indications are not published in the Drug Product Database — see… | DIN02326442 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| May 14, 2009 | Interferon Beta-1a | Health Canada CA | cancer not stated in this record | Marketed in Canada as REBIF (DIN 02318253) under ATC L03AB07 INTERFERON BETA-1A. Indications are not published in the Drug Product Database… | DIN02318253 | approvedsource: Marketed | health-canada-dpd |
| May 4, 2009 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as SPRYCEL (DIN 02320193) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see… | DIN02320193 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jul 20, 2021 |
| health-canada-dpd |
| Mar 24, 2009 | Epirubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as EPIRUBICIN HYDROCHLORIDE INJECTION (DIN 02312093) under ATC L01DB03 EPIRUBICIN. Indications are not published in the… | DIN02312093 | withdrawnsource: Dormantsince Jun 19, 2015 | health-canada-dpd |
| Mar 20, 2009 | Bleomycin | Health Canada CA | cancer not stated in this record | Marketed in Canada as BLEOMYCIN FOR INJECTION (DIN 02265982) under ATC L01DC01 BLEOMYCIN. Indications are not published in the Drug Product… | DIN02265982 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jul 22, 2011 |
| health-canada-dpd |
| Feb 21, 2009 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEMODAL (DIN 02312794) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database —… | DIN02312794 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince May 19, 2017 |
| health-canada-dpd |
| Jan 26, 2009 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METOJECT (DIN 02320045) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database —… | DIN02320045 | withdrawnsource: Cancelled Post Marketsince Jul 17, 2019 | health-canada-dpd |
| Jan 26, 2009 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METOJECT (DIN 02320037) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database —… | DIN02320037 | withdrawnsource: Cancelled Post Marketsince Apr 23, 2020 | health-canada-dpd |
| Jan 26, 2009 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METOJECT (DIN 02320029) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database —… | DIN02320029 | withdrawnsource: Cancelled Post Marketsince Jun 29, 2022 | health-canada-dpd |
| Jan 9, 2009 | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as ALIMTA (DIN 02306433) under ATC L01BA04 PEMETREXED. Indications are not published in the Drug Product Database — see… | DIN02306433 | withdrawnsource: Cancelled Post Marketsince Jan 29, 2026 | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Oct 3, 2012 |
| health-canada-dpd |
| Nov 24, 2008 | Epirubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as EPIRUBICIN HYDROCHLORIDE INJECTION (DIN 02264927) under ATC L01DB03 EPIRUBICIN. Indications are not published in the… | DIN02264927 | withdrawnsource: Cancelled Post Marketsince Sep 4, 2017 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Oct 28, 2008 | Cetuximab | Health Canada CA | cancer not stated in this record | Marketed in Canada as ERBITUX (DIN 02271249) under ATC L01FE01 CETUXIMAB. Indications are not published in the Drug Product Database — see… | DIN02271249 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |